Literature DB >> 18060447

Acute coronary syndrome as a first presentation of systemic lupus erythematosus in a teenager: revascularization by hybrid coronary artery bypass graft surgery and percutaneous coronary intervention: case report.

P K Mehta1, H Samady, T A Vassiliades, W M Book.   

Abstract

Patients with systemic lupus erythematosus (SLE) may present with acute coronary syndrome (ACS) due to coronary vasculitis or premature atherosclerosis. There is a paucity of data on invasive management strategies for young adults who present with an ACS secondary to active vasculitis. This article describes the case of a teenager who presented with an ACS secondary to lupus vasculitis as his first presentation of active SLE. Coronary angiography showed a left main equivalent lesion involving a proximal very large left anterior descending artery (LAD) and diagonal stenosis (with a diminutive left circumflex artery). The boy underwent a successful endoscopic coronary bypass surgery to his LAD followed by percutaneous coronary intervention to his diagonal artery. This case demonstrates the feasibility and safety of a hybrid coronary revascularization in a teenager with acute coronary syndrome due to coronary vasculitis.

Entities:  

Mesh:

Year:  2007        PMID: 18060447     DOI: 10.1007/s00246-007-9157-0

Source DB:  PubMed          Journal:  Pediatr Cardiol        ISSN: 0172-0643            Impact factor:   1.655


  12 in total

Review 1.  Spontaneous coronary artery dissection in a young woman treated with extensive coronary stenting.

Authors:  K M Leclerc; A M Mascette; D T Schachter; A B Wicks
Journal:  J Invasive Cardiol       Date:  1999-04       Impact factor: 2.022

2.  Spontaneous dissection of coronary artery treated by primary stenting as the first presentation of systemic lupus erythematosus.

Authors:  A H Sami Aldoboni; E Amir Hamza; K Majdi; M Ngibzadhe; S Palasaidi; D Akhlag Moayed
Journal:  J Invasive Cardiol       Date:  2002-11       Impact factor: 2.022

Review 3.  Cardiovascular involvement in systemic lupus erythematosus.

Authors:  B F Mandell
Journal:  Semin Arthritis Rheum       Date:  1987-11       Impact factor: 5.532

Review 4.  Coronary artery disease in systemic lupus erythematosus: A review of the literature.

Authors:  A Karrar; W Sequeira; J A Block
Journal:  Semin Arthritis Rheum       Date:  2001-06       Impact factor: 5.532

5.  Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden.

Authors:  Bo Lagerqvist; Stefan K James; Ulf Stenestrand; Johan Lindbäck; Tage Nilsson; Lars Wallentin
Journal:  N Engl J Med       Date:  2007-02-12       Impact factor: 91.245

6.  A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents.

Authors:  Christian Spaulding; Joost Daemen; Eric Boersma; Donald E Cutlip; Patrick W Serruys
Journal:  N Engl J Med       Date:  2007-02-12       Impact factor: 91.245

7.  [Cardiac involvement in systemic autoimmune disease].

Authors:  Jerzy Dropiński; Wojciech Szczeklik; Paweł Rubiś
Journal:  Pol Arch Med Wewn       Date:  2003-04

8.  Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus.

Authors:  S Manzi; F Selzer; K Sutton-Tyrrell; S G Fitzgerald; J E Rairie; R P Tracy; L H Kuller
Journal:  Arthritis Rheum       Date:  1999-01

9.  Coronary arterial disease in systemic lupus erythematosus; quantification of degrees of narrowing in 22 necropsy patients (21 women) aged 16 to 37 years.

Authors:  Y S Haider; W C Roberts
Journal:  Am J Med       Date:  1981-04       Impact factor: 4.965

10.  Myocardial perfusion scintigraphy and coronary disease risk factors in systemic lupus erythematosus.

Authors:  E M C Sella; E I Sato; W A Leite; J A Oliveira Filho; A Barbieri
Journal:  Ann Rheum Dis       Date:  2003-11       Impact factor: 19.103

View more
  1 in total

1.  Recurrent very late stent thrombosis in a systemic lupus erythematous patient.

Authors:  Dong-Yob Lee; Jong-Pil Park; Sung-Jun Ko; Shin-Eun Lee; Sung-Hee Jhon; Ji-Hyun Lim; Jay-Young Rhew
Journal:  Korean Circ J       Date:  2012-02-27       Impact factor: 3.243

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.